Effect of Diabetes Mellitus on Symptomatic Improvement After Surgery for Benign Prostatic Hyperplasia in Patients With Lower Urinary Tract Symptom and its Relations With Prostatic Urethral Angulation
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To compare improvement of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia in diabetic versus nondiabetic patients after transurethral resection of the prostate (TURP) or holmium laser enucleation of the prostate (HoLEP). Methods: The medical records of 437 patients who underwent TURP or HoLEP at a tertiary referral center from January 2006 to January 2022 were retrospectively analyzed. Among them, 71 patients had type 2 diabetes. Patients in the diabetic mellitus (DM) and non-DM groups were matched 1:1 according to age, baseline International Prostate Symptom Score (IPSS), and ultrasound measured prostate volume. Changes in LUTS were assessed at 3 months after surgery using IPSS and evaluated by categorizing patients according to prostatic urethral angulation (PUA; <50° vs. ≥50°). Medication-free survival after surgery was also investigated. Results: No significant differences were noted between the DM and non-DM groups in baseline characteristics except for comorbidities (i.e., hypertension, cerebrovascular disease, and ischemic heart disease, P=0.021, P=0.002, and P=0.017, respectively) and postvoid residual urine volume (115±98 mL vs. 76±105 mL, P=0.028). Non-DM patients showed significant symptomatic improvement regardless of PUA, while DM patients demonstrated improvement in obstructive symptoms only in those with large PUA (≥51°). Among patients with small PUA, DM patients had worse medication-free survival after surgery compared to controls (P=0.044) and DM was an independent predictor of medication reuse (hazard ratio, 1.422; 95% confidence interval, 1.285–2.373; P=0.038). Conclusions: DM patients experienced symptomatic improvement after surgery only in those with large PUA. Among patients with small PUA, DM patients were more likely to reuse medication after surgery.
Abstract
Purpose: To compare improvement of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia in diabetic versus nondiabetic patients after transurethral resection of the prostate (TURP) or holmium laser enucleation of the prostate (HoLEP). Methods: The medical records of 437 patients who underwent TURP or HoLEP at a tertiary referral center from January 2006 to January 2022 were retrospectively analyzed. Among them, 71 patients had type 2 diabetes. Patients in the diabetic mellitus (DM) and non-DM groups were matched 1:1 according to age, baseline International Prostate Symptom Score (IPSS), and ultrasound measured prostate volume. Changes in LUTS were assessed at 3 months after surgery using IPSS and evaluated by categorizing patients according to prostatic urethral angulation (PUA; <50° vs. ≥50°). Medication-free survival after surgery was also investigated. Results: No significant differences were noted between the DM and non-DM groups in baseline characteristics except for comorbidities (i.e., hypertension, cerebrovascular disease, and ischemic heart disease, P=0.021, P=0.002, and P=0.017, respectively) and postvoid residual urine volume (115±98 mL vs. 76±105 mL, P=0.028). Non-DM patients showed significant symptomatic improvement regardless of PUA, while DM patients demonstrated improvement in obstructive symptoms only in those with large PUA (≥51°). Among patients with small PUA, DM patients had worse medication-free survival after surgery compared to controls (P=0.044) and DM was an independent predictor of medication reuse (hazard ratio, 1.422; 95% confidence interval, 1.285–2.373; P=0.038). Conclusions: DM patients experienced symptomatic improvement after surgery only in those with large PUA. Among patients with small PUA, DM patients were more likely to reuse medication after surgery.
참고문헌 (21)
- Guess HA, "Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia", Prostate, 17, pp.241~246 (1990)
- Litman HJ, "The future magnitude of urological symptoms in the USA : projections using the Boston Area Community Health survey", BJU Int, 100, pp.820~825 (2007)
- 조정기, "Changes in Prevalence and Treatment Pattern of Benign Prostatic Hyperplasia in Korea", International Neurourology Journal, 25(4), pp.347~354 (2021), 대한배뇨장애요실금학회[DOI]
- Sarma AV, "Diabetes and benign prostatic hyperplasia : emerging clinical connections", Curr Urol ReP, 10, pp.267~275 (2009)
- Pourghasem M, "Histological changes of kidney in diabetic nephropathy", Caspian J Intern Med, 6, pp.120~127 (2015)
- Sasaki K, "Implications of diabetes mellitus in urology", Urol Clin North Am, 30, pp.1~12 (2003)
- Sarma AV, "Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling black and white men", Diabetes Care, 31, pp.476~482 (2008)
- Michel MC, "Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia", J Urol, 163, pp.1725~1729 (2000)
- Stamatiou K, "The impact of diabetes type 2 in the pathogenesis of benign prostatic hyperplasia : a review", Adv Urol, 2009, pp.818965~ (2009)
- Lin KH, "Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia", Aging Male, 15, pp.246~242 (2012)
- Kim EH, "Management of benign prostatic hyperplasia", Annu Rev Med, 67, pp.137~151 (2016)
- Christidis D, "Minimally invasive surgical therapies for benign prostatic hypertrophy : the rise in minimally invasive surgical therapies", Prostate Int, 5, pp.41~46 (2017)
- Shim M, "Correlation between prostatic urethral angulation and symptomatic improvement after surgery in patients with lower urinary tract symptoms according to prostate size", World J Urol, 38, pp.1997~2003 (2020)
- Hammarsten J, "Urological aspects of the metabolic syndrome", Nat Rev Urol, 8, pp.483~494 (2011)
- McVary KT, "Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia", J Urol, 174, pp.1327~1433 (2005)
- Sampson N, "Stromal insulin-like growth factor binding protein 3(IGFBP3)is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation", Endocrinology, 154, pp.2586~2599 (2013)
- Jangir RN, "Diabetes mellitus induced impairment of male reproductive functions : a review", Curr Diabetes Rev, 10, pp.147~157 (2014)
- Parsons JK, "Metabolic factors associated with benign prostatic hyperplasia", J Clin Endocrinol Metab, 91, pp.2562~2568 (2006)
- Zhu Y, "Detrusor underactivity influences the efficacy of TURP in patients with BPO", Int Urol Nephrol, 53, pp.835~841 (2021)
- Lin YH, "Is diabetes mellitus associated with clinical outcomes in aging males treated with transurethral resection of prostate for bladder outlet obstruction : implications from Taiwan Nationwide Populationbased cohort study", Clin Interv Aging, 12, pp.535~541 (2017)
- 최훈, "Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study", International Neurourology Journal, 22(1), pp.51~57 (2018), 대한배뇨장애요실금학회